Literature DB >> 12408897

Determination of doxorubicin and its metabolites in rat serum and bile by LC: application to preclinical pharmacokinetic studies.

Qingyu Zhou1, Balram Chowbay.   

Abstract

A simple, accurate and precise high-performance liquid chromatographic method was developed and validated for the simultaneous determination of doxorubicin and its three metabolites, including doxorubicinol, doxorubicinolone and doxorubicinone, in rat serum and bile. Following a single protein precipitation step, chromatographic separation was accomplished using a C-18 column with a mobile phase consisting of 50 mM sodium phosphate buffer-acetonitrile-1-propanol (65:25:2, v/v), pH 2.0. The analytes were measured by fluorescence detection with excitation wavelength of 480 nm and emission wavelength of 560 nm. The lower limits of quantitation were 10 ng/ml for doxorubicin, and 5 ng/ml for the three metabolites. The calibration curves were linear over a concentration range of 10-2500 ng/ml for doxorubicin, and 5-1250 ng/ml for its three metabolites. The average recoveries were greater than 89% for all analytes. The within-day and between-day coefficients of variation were generally less than 13%. Doxorubicin and its metabolites were stable in the precipitated serum and bile samples at room temperature in darkness for at least 48 h. This method permitted the analysis of samples without the presence of the anticoagulant sodium citrate and thus was applied to serum and bile samples collected from rats that were administered doxorubicin intravenously in a pharmacokinetic study.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12408897     DOI: 10.1016/s0731-7085(02)00442-9

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  6 in total

1.  Quantification of Doxorubicin and metabolites in rat plasma and small volume tissue samples by liquid chromatography/electrospray tandem mass spectroscopy.

Authors:  Robert D Arnold; Jeanine E Slack; Robert M Straubinger
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2004-09-05       Impact factor: 3.205

2.  Liver cancer targeting of Doxorubicin with reduced distribution to the heart using hematoporphyrin-modified albumin nanoparticles in rats.

Authors:  Ji-Eun Chang; Won-Sik Shim; Su-Geun Yang; Eun-Young Kwak; Saeho Chong; Dae-Duk Kim; Suk-Jae Chung; Chang-Koo Shim
Journal:  Pharm Res       Date:  2011-10-05       Impact factor: 4.200

3.  Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer.

Authors:  Paul R Lockman; Rajendar K Mittapalli; Kunal S Taskar; Vinay Rudraraju; Brunilde Gril; Kaci A Bohn; Chris E Adkins; Amanda Roberts; Helen R Thorsheim; Julie A Gaasch; Suyun Huang; Diane Palmieri; Patricia S Steeg; Quentin R Smith
Journal:  Clin Cancer Res       Date:  2010-09-09       Impact factor: 12.531

4.  Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.

Authors:  Yong-Yu Liu; Vineet Gupta; Gauri A Patwardhan; Kaustubh Bhinge; Yunfeng Zhao; Jianxiong Bao; Harihara Mehendale; Myles C Cabot; Yu-Teh Li; S Michal Jazwinski
Journal:  Mol Cancer       Date:  2010-06-11       Impact factor: 27.401

5.  Attenuation effect of Abnormal Savda Munziq on liver and heart toxicity caused by chemotherapy in mice.

Authors:  Ainiwaer Aikemu; Nurmuhamat Amat; Abdiryim Yusup; Lianlian Shan; Xinwei Qi; Halmurat Upur
Journal:  Exp Ther Med       Date:  2016-05-10       Impact factor: 2.447

6.  Liquid Chromatography-Tandem Mass Spectrometry for the Simultaneous Determination of Doxorubicin and its Metabolites Doxorubicinol, Doxorubicinone, Doxorubicinolone, and 7-Deoxydoxorubicinone in Mouse Plasma.

Authors:  Won-Gu Choi; Dong Kyun Kim; Yongho Shin; Ria Park; Yong-Yeon Cho; Joo Young Lee; Han Chang Kang; Hye Suk Lee
Journal:  Molecules       Date:  2020-03-10       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.